Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective lowered by equities research analysts at Guggenheim from $24.00 to $23.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target would indicate a potential upside of 101.14% from the stock’s current price.

A number of other brokerages also recently issued reports on ZVRA. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 27th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. BTIG Research lowered their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Finally, Maxim Group boosted their price target on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Nine analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.14.

Zevra Therapeutics Stock Down 3.7%

Shares of NASDAQ:ZVRA traded down $0.45 during midday trading on Friday, reaching $11.44. 490,420 shares of the company traded hands, compared to its average volume of 1,363,010. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03. The firm has a market capitalization of $676.04 million, a price-to-earnings ratio of 12.39 and a beta of 0.91. The firm’s fifty day moving average price is $12.32 and its two-hundred day moving average price is $10.57.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. Zevra Therapeutics had a return on equity of 58.95% and a net margin of 42.82%. Analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Hedge Funds Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Zevra Therapeutics during the 4th quarter valued at $53,000. Russell Investments Group Ltd. lifted its stake in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Creative Planning purchased a new position in shares of Zevra Therapeutics in the 2nd quarter worth about $92,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Zevra Therapeutics during the 2nd quarter valued at about $99,000. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.